MORGAN Stanley estimates Pfizer will rake in nearly $100 billion – the equivalent of around R1.35 trillion – from Covid-19 vaccine sales over the next five years.
Pfizer’s Covid-19 vaccine will earn about $96.1 billion by 2025, primarily during this year and next when demand for vaccines is the highest, Morgan Stanley said in an analyst note released May 9.
Morgan Stanley tripled its prior estimate of $32 billion in revenue for Covid-19 vaccine sales over a four-year span.
The bank said its projection is contingent on if the World Trade Organisation does not lift vaccine patents, but said the firm will “watch future news.”
World leaders, humanitarians, doctors, and other interest groups are to suspend vaccine patents, by way of a waiver at the World Trade Organisation. The move would lift intellectual property rights of pharmaceutical firms and allow drugmakers around the world to replicate the vaccine.
Morgan Stanley’s
You’ve reached your free article limit
Subscribe to enjoy unlimited access to trusted journalism. Cancel anytime.
Subscribe nowNeed help? molokom@insidepolitic.co.za
